A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of Merck & Co. Inc. MRK slipped 1.46% to $93.35 Wednesday, on what proved to be an all-around mixed trading session ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

After hours: March 12 at 7:58:13 PM EDT Loading Chart for MRK ...